AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26122686 — intervention group
Group type: COMPARATOR
Intervention: Home exercise program
Number of subjects: 99
Study 24114693 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-time schedule of brief breaks (noncontingent escape) from ongoing dental treatment
Number of subjects: 151
Study 24114693 — intervention group
Group type: COMPARATOR
Intervention: Usual behavior management
Number of subjects: 151
Study 21079764 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive viewing of global structure
Number of subjects: 8
Study 21079764 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal Glass patterns
Number of subjects: 8
Study 21079764 — intervention group
Group type: EXPERIMENTAL
Intervention: Radial and rotational Glass patterns
Number of subjects: 8
Study 21079764 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual area V3a
Number of subjects: 8
Study 21079764 — intervention group
Group type: COMPARATOR
Intervention: Visual area V1
Number of subjects: 8
Study 18430652 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial surgical radiofrequency ablation
Number of subjects: 357
Study 16837929 — intervention group
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula CPAP
Number of subjects: 40
Study 16837929 — intervention group
Group type: COMPARATOR
Intervention: Infant Flow Nasal CPAP
Number of subjects: 40
Study 12946763 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg once daily for 28 days
Number of subjects: 377
Study 12946763 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice daily for 28 days
Number of subjects: 377
Study 10400480 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine nasal spray (2 sprays per nostril bid, 1.1 mg/day)
Number of subjects: 1070
Study 10400480 — intervention group
Group type: COMPARATOR
Intervention: Combination therapy with loratadine (10 mg/day) and beclomethasone (2 sprays per nostril bid, 336 microg/day)
Number of subjects: 1070
Study 8723848 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac 60 mg, administered intramuscularly 30 minutes before surgery
Number of subjects: 60
Study 8723848 — intervention group
Group type: COMPARATOR
Intervention: Saline (placebo), administered intramuscularly 30 minutes before surgery
Number of subjects: 60
Study 1878075 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcoholic beverages (40 g alcohol) in the form of beer, red wine, or spirits
Number of subjects: 8
Study 1878075 — intervention group
Group type: COMPARATOR
Intervention: Mineral water (control)
Number of subjects: 8
Study 7470395 — intervention group
Group type: EXPERIMENTAL
Intervention: British Comparative Thromboplastin (BCT)
Number of subjects: 0
Study 7470395 — intervention group
Group type: EXPERIMENTAL
Intervention: Amidolytic assays for factors II and X
Number of subjects: 0
Study 7470395 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromogenic substrate assays
Number of subjects: 0
Study 7470395 — intervention group
Group type: EXPERIMENTAL
Intervention: Factor II and X amidolytic methods
Number of subjects: 0
Study 7470395 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific amidolytic assay for factor VII
Number of subjects: 0
Study 31675390 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered collaborative care for depression
Number of subjects: 301
Study 31675390 — intervention group
Group type: COMPARATOR
Intervention: Usual care by physician
Number of subjects: 301
Study 31055192 — intervention group
Group type: EXPERIMENTAL
Intervention: BioFreedom drug-coated stent
Number of subjects: 3150
Study 31055192 — intervention group
Group type: COMPARATOR
Intervention: Orsiro biodegradable polymer stent
Number of subjects: 3150
Study 28245700 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based video teleconferencing
Number of subjects: 22
Study 28245700 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 22
Study 25940684 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb training protocols (90 to 120 minutes of intervention every weekday for 3 to 4 weeks)
Number of subjects: 95
Study 23751277 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 29
Study 23751277 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/day
Number of subjects: 29
Study 23751277 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 21281870 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 65
Study 21281870 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 65
Study 19448327 — intervention group
Group type: EXPERIMENTAL
Intervention: Nocturnal oxygen therapy (HOT)
Number of subjects: 51
Study 19448327 — intervention group
Group type: COMPARATOR
Intervention: Usual breathing (control)
Number of subjects: 51
Study 16829499 — intervention group
Group type: EXPERIMENTAL
Intervention: Flicking-off with a plastic instrument 3 min after initial polymerization
Number of subjects: 0
Study 16829499 — intervention group
Group type: COMPARATOR
Intervention: Wiping action with cotton pellets
Number of subjects: 0
Study 14601712 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 10676602 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (10 mg once daily)
Number of subjects: 50
Study 10676602 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 mg once daily)
Number of subjects: 50
Study 8476721 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxyvitamin D3
Number of subjects: 0
Study 8476721 — intervention group
Group type: EXPERIMENTAL
Intervention: dihydrotachysterol
Number of subjects: 0
Study 2869772 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg by mouth (as soft gelatin capsules) followed at 35 min by i.v. saline
Number of subjects: 39
Study 2869772 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo followed at 35 min by i.v. diazepam 10 mg (Diazemuls)
Number of subjects: 39
Study 2869772 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 40 mg by mouth (as soft gelatin capsules)
Number of subjects: 39
Study 30371148 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 125 mg
Number of subjects: 28
Study 30371148 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 100 mg
Number of subjects: 28
Study 30371148 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA 40 mg (low dose)
Number of subjects: 28
Study 30371148 — intervention group
Group type: EXPERIMENTAL
Intervention: MDMA (all active doses)
Number of subjects: 28
Study 27150317 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS (1 mA, 10 min)
Number of subjects: 14
Study 27150317 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS (1 mA, 10 min)
Number of subjects: 14
Study 27150317 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS (1 mA, 10 min)
Number of subjects: 14
Study 27150317 — intervention group
Group type: EXPERIMENTAL
Intervention: All tDCS conditions (anodal, cathodal, sham)
Number of subjects: 14
Study 27150317 — intervention group
Group type: EXPERIMENTAL
Intervention: Group level analysis of tDCS effects
Number of subjects: 14
Study 24970869 — intervention group
Group type: EXPERIMENTAL
Intervention: Paricalcitol (1 μg/d)
Number of subjects: 110
Study 24970869 — intervention group
Group type: COMPARATOR
Intervention: Calcitriol (0.25 μg/d)
Number of subjects: 110
Study 24970869 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 110
Study 22801093 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole Prophylactic Treatment (CPT)
Number of subjects: 0
Study 20482348 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination headgear (HG)
Number of subjects: 99
Study 20482348 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 99
Study 18688081 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A5 3 allele
Number of subjects: 317
Study 18688081 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP3A4 1B allele
Number of subjects: 317
Study 18688081 — intervention group
Group type: EXPERIMENTAL
Intervention: MDR1 T allele
Number of subjects: 317
Study 15735111 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily multiple micronutrient (DMM) supplementation
Number of subjects: 306
Study 15735111 — intervention group
Group type: COMPARATOR
Intervention: Daily placebo (P) supplementation
Number of subjects: 306
Study 15735111 — intervention group
Group type: COMPARATOR
Intervention: Weekly multiple micronutrient (WMM) supplementation
Number of subjects: 306
Study 15735111 — intervention group
Group type: COMPARATOR
Intervention: Daily iron (DI) supplementation
Number of subjects: 306
Study 12057733 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRHa (3.75 mg/4 weeks of triptorelin or 3.6 mg/4 weeks of goserelin)
Number of subjects: 32
Study 12057733 — intervention group
Group type: COMPARATOR
Intervention: No GnRHa
Number of subjects: 32
Study 10342616 — intervention group
Group type: EXPERIMENTAL
Intervention: Squeezable feeding bottle (assisted feeding)
Number of subjects: 101
Study 10342616 — intervention group
Group type: COMPARATOR
Intervention: Rigid feeding bottle
Number of subjects: 101
Study 8962906 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (severe chronic hepatitis)
Number of subjects: 36
Study 8962906 — intervention group
Group type: COMPARATOR
Intervention: Group B (mild/moderate chronic hepatitis)
Number of subjects: 36
Study 1430613 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated phobics
Number of subjects: 38
Study 1430613 — intervention group
Group type: COMPARATOR
Intervention: Untreated phobics
Number of subjects: 38
Study 6377563 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihomo-gamma-linolenic acid (DHLA) 1.0 g daily for 4 weeks
Number of subjects: 33
Study 6377563 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 31326135 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Knee Replacement (PKR)
Number of subjects: 528
Study 31326135 — intervention group
Group type: COMPARATOR
Intervention: Total Knee Replacement (TKR)
Number of subjects: 528
Study 30315178 — intervention group
Group type: EXPERIMENTAL
Intervention: Overweight children (OW)
Number of subjects: 71
Study 30315178 — intervention group
Group type: COMPARATOR
Intervention: Healthy weight children (HW)
Number of subjects: 71
Study 30315178 — intervention group
Group type: EXPERIMENTAL
Intervention: Percent fat
Number of subjects: 71
Study 30315178 — intervention group
Group type: EXPERIMENTAL
Intervention: CRP
Number of subjects: 71
Study 30315178 — intervention group
Group type: EXPERIMENTAL
Intervention: TNFα
Number of subjects: 71
Study 26024672 — intervention group
Group type: EXPERIMENTAL
Intervention: School-based smoking prevention program (Eigenständig werden 5+6)
Number of subjects: 0
Study 26024672 — intervention group
Group type: EXPERIMENTAL
Intervention: Normative expectations concerning peer smoking
Number of subjects: 0
Study 26024672 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance skill of saying 'no'
Number of subjects: 0
Study 24783961 — intervention group
Group type: EXPERIMENTAL
Intervention: EB4K with Play intervention
Number of subjects: 844
Study 24783961 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 844
Study 22885561 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate to high soy genistein intake
Number of subjects: 300
Study 22885561 — intervention group
Group type: COMPARATOR
Intervention: Little or no soy genistein intake
Number of subjects: 300
Study 19656436 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week trial lifestyle intervention
Number of subjects: 55
Study 18823196 — intervention group
Group type: EXPERIMENTAL
Intervention: High perceptual load in a letter-search task
Number of subjects: 0
Study 18823196 — intervention group
Group type: COMPARATOR
Intervention: Low perceptual load in a letter-search task
Number of subjects: 0
Study 15716202 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg po qhs for at least 4 weeks
Number of subjects: 98
Study 11834123 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose glutamine (0.3 g x kg(‐1))
Number of subjects: 6
Study 11834123 — intervention group
Group type: COMPARATOR
Intervention: Glycine (0.3 g x kg(‐1))
Number of subjects: 6
Study 11834123 — intervention group
Group type: COMPARATOR
Intervention: Placebo (calorie-free fruit juice only)
Number of subjects: 6
Study 10320226 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1 (n = 6)
Number of subjects: 12
Study 10320226 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control group, n = 6)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: felodipine 10 mg (single dose)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 12.5 mg (single dose)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: felodipine 10 mg b.i.d. (steady-state)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: HCTZ 12.5 mg b.i.d. (steady-state)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: felodipine (any dose)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: HCTZ (any dose)
Number of subjects: 12
Study 7720759 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 1462915 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-balloon technique (group A)
Number of subjects: 45
Study 1462915 — intervention group
Group type: EXPERIMENTAL
Intervention: Inoue single-balloon technique (group B)
Number of subjects: 45
Study 1462915 — intervention group
Group type: COMPARATOR
Intervention: Control group (group A)
Number of subjects: 45
Study 6581062 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoterol inhalation powder
Number of subjects: 9
Study 6581062 — intervention group
Group type: COMPARATOR
Intervention: Fenoterol metered dose inhaler
Number of subjects: 9
Study 31732876 — intervention group
Group type: EXPERIMENTAL
Intervention: ECOG score 0
Number of subjects: 3143
Study 31732876 — intervention group
Group type: COMPARATOR
Intervention: ECOG score 1
Number of subjects: 3143
Study 30116855 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs)
Number of subjects: 0
Study 30116855 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak and strong opioids
Number of subjects: 0
Study 30116855 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-opioid medications (e.g., paracetamol, metamizole)
Number of subjects: 0
Study 30116855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26903582 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial treatment (IAT) with retrievable stents
Number of subjects: 0
Study 26903582 — intervention group
Group type: COMPARATOR
Intervention: No intra-arterial treatment (Control)
Number of subjects: 0
Study 22183173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg with low-fat meal
Number of subjects: 0
Study 22183173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg with moderate-fat meal
Number of subjects: 0
Study 22183173 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir 50 mg with high-fat meal
Number of subjects: 0
Study 22183173 — intervention group
Group type: COMPARATOR
Intervention: Dolutegravir 50 mg in fasted state
Number of subjects: 0
Study 19558712 — intervention group
Group type: EXPERIMENTAL
Intervention: Well London project interventions focusing on healthy eating, physical activity, and mental health and wellbeing, implemented in 20 areas.
Number of subjects: 40
Study 19558712 — intervention group
Group type: COMPARATOR
Intervention: Control group of matched areas not receiving the Well London project interventions.
Number of subjects: 40
Study 17029554 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing mastic gum for 15 minutes
Number of subjects: 0
Study 17029554 — intervention group
Group type: EXPERIMENTAL
Intervention: Chewing mastic gum for 135 minutes
Number of subjects: 0
Study 17029554 — intervention group
Group type: COMPARATOR
Intervention: Control (chewing paraffin)
Number of subjects: 0
Study 16610179 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-closure of peritoneum
Number of subjects: 80
Study 16610179 — intervention group
Group type: COMPARATOR
Intervention: Closure of peritoneum
Number of subjects: 80
Study 11907660 — intervention group
Group type: EXPERIMENTAL
Intervention: COPD patients requiring mechanical ventilation
Number of subjects: 63
Study 11907660 — intervention group
Group type: COMPARATOR
Intervention: Stable COPD patients on long-term oxygen therapy
Number of subjects: 63
Study 11122795 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary therapy
Number of subjects: 0
Study 11122795 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy with autologous hematopoietic support
Number of subjects: 0
Study 11122795 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel node biopsy
Number of subjects: 0
Study 11122795 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic markers
Number of subjects: 0
Study 8800784 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized 17 beta‐oestradiol (2 mg/day) continuously with dydrogesterone (10 mg/day) for the first 14 days of each cycle
Number of subjects: 48
Study 2192334 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal treatment (scaling, root planing, and periodontal surgery)
Number of subjects: 10
Study 2192334 — intervention group
Group type: COMPARATOR
Intervention: Control (contralateral teeth)
Number of subjects: 10
Study 7382628 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxine alone
Number of subjects: 40
Study 7382628 — intervention group
Group type: COMPARATOR
Intervention: Digoxine plus amiodarone hydrochloride
Number of subjects: 40
Study 31048187 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocellular dressings (ALLEVYN Adhesive®)
Number of subjects: 169
Study 31048187 — intervention group
Group type: COMPARATOR
Intervention: Hydrocolloid dressings (VARIHESIVE® GEL CONTROL)
Number of subjects: 169
Study 28714725 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use prevention (SP) intervention
Number of subjects: 4158
Study 28714725 — intervention group
Group type: COMPARATOR
Intervention: Comparison intervention (energy balance behaviors)
Number of subjects: 4158
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic load perception in stroke survivors
Number of subjects: 10
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination in stroke survivors
Number of subjects: 10
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioception in stroke survivors
Number of subjects: 10
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance in stroke survivors
Number of subjects: 10
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Gait symmetry in stroke survivors
Number of subjects: 10
Study 25097091 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of gait symmetry with static and dynamic load perception measures
Number of subjects: 10
Study 25228971 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-look endoscopy (SLE)
Number of subjects: 437
Study 25228971 — intervention group
Group type: COMPARATOR
Intervention: Non-second-look endoscopy (non-SLE)
Number of subjects: 437
Study 25228971 — intervention group
Group type: EXPERIMENTAL
Intervention: SLE for lesions with a large tumor size (>20 mm)
Number of subjects: 437
Study 25228971 — intervention group
Group type: COMPARATOR
Intervention: Non-SLE for lesions with a large tumor size (>20 mm)
Number of subjects: 437
Study 23161301 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alfa‐2a (40KD; 180 μg/week)
Number of subjects: 113
Study 18722086 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of Assessing Treatment Delivery (MATD)
Number of subjects: 0
Study 17484873 — intervention group
Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 31
Study 15172894 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal budesonide for 2 weeks
Number of subjects: 20
Study 15172894 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 12297843 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal albumin dialysis (ECAD)
Number of subjects: 24
Study 12297843 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy (SMT)
Number of subjects: 24
Study 9839843 — intervention group
Group type: EXPERIMENTAL
Intervention: PES at 100 Hz
Number of subjects: 9
Study 9839843 — intervention group
Group type: COMPARATOR
Intervention: PES at 20 Hz
Number of subjects: 9
Study 8088139 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% SLS solution
Number of subjects: 11
Study 8088139 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% SLS solution
Number of subjects: 11
Study 8088139 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% SLS solution
Number of subjects: 11
Study 8088139 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5% SLS solution
Number of subjects: 11
Study 8088139 — intervention group
Group type: COMPARATOR
Intervention: Deionized water (control)
Number of subjects: 11
Study 2732866 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid refeeding (RR)
Number of subjects: 52
Study 2732866 — intervention group
Group type: COMPARATOR
Intervention: Gradual refeeding (GR)
Number of subjects: 52
Study 1234581 — intervention group
Group type: EXPERIMENTAL
Intervention: Constant insulin doses
Number of subjects: 43
Study 1234581 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable insulin doses
Number of subjects: 43
Study 1234581 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of biguanides (metformin)
Number of subjects: 43
Study 1234581 — intervention group
Group type: COMPARATOR
Intervention: Control group (no biguanides)
Number of subjects: 43
Study 31691287 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment factors (perceptions of safety and support, student attitudes to learning)
Number of subjects: 2278
Study 31691287 — intervention group
Group type: EXPERIMENTAL
Intervention: School environment
Number of subjects: 2278
Study 31691287 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 2278
Study 28063908 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonic energy
Number of subjects: 20
Study 28063908 — intervention group
Group type: COMPARATOR
Intervention: Monopolar energy
Number of subjects: 20
Study 28063908 — intervention group
Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 20
Study 28063908 — intervention group
Group type: COMPARATOR
Intervention: Nonbarbed suture
Number of subjects: 20